Medicines / Ipca Laboratories / Revelol T AM

Revelol T AMTelmisartan + Metoprolol + Amlodipine

Revelol T AM is marketed by Ipca Laboratories. 1 pack on NPPA's price list for July 2026, containing Telmisartan + Metoprolol + Amlodipine.

Packs listed
1
Lowest MRP
₹161.00
Per unit
₹16.10
Price-controlled packs
0 of 1
Dosage forms
1

Packs and prices

  1. ₹161.00Revelol T AM 40/50/5 mg Tablet 10Telmisartan + Metoprolol + Amlodipine Tablet 40/50/5 mg · ₹16.10 per tablet

The same composition from other brands

Packs with the identical filed composition, form and strength. A different brand is not automatically interchangeable: ask your doctor or pharmacist.

Telmisartan + Metoprolol + Amlodipine Tablet 40/50/5 mg

  1. ₹14.90/tabletTelbira 3D · 10 tabletAptus Pharma · MRP ₹149.00
  2. ₹15.19/tabletTelma Beta AM · 10 tabletGlenmark Pharmaceuticals · MRP ₹151.87
  3. ₹15.94/tabletTrianta Amt · 10 tabletAjanta Pharma · MRP ₹159.37
  4. ₹16.73/tabletMetocard Amt · 10 tabletTorrent Pharmaceuticals · MRP ₹167.29
  5. ₹16.78/tabletMetosartan AM · 10 tabletSun Pharma Laboratories · MRP ₹167.81

5 other brands of this composition on the price list; the 5 lowest per tablet are shown. All Telmisartan + Metoprolol + Amlodipine packs

The company

Ipca Laboratories has 796 packs on the price list, and CDSCO has named it as the manufacturer of 15 failed batches since Dec 2015. Company record

Prices are the maximum retail prices each company filed with the National Pharmaceutical Pricing Authority (NPPA) for July 2026, read from NPPA's Pharma Sahi Daam service on 2 Oct 2026. A price in a shop can be lower; it may not lawfully be higher. Failed batches are those CDSCO and state laboratories declared not of standard quality. This is a record of prices and filings, not medical advice: do not change a medicine without your doctor or pharmacist. Source: NPPA and CDSCO, Government of India. About this record.

COUNTERFOIL / CONTACT

Contact us.

How can we help?

Stored privately by Counterfoil. Your email is used only to respond to your enquiry.